journal article·2017-12-13

A Dual Macrophage Targeting Nanovector for Delivery of Oligodeoxynucleotides To Overcome Cancer-Associated Immunosuppression

Xiao-Yan He, Bo-Ya Liu, Jin-Long Wu, Shu-Lun Ai, Ren-Xi Zhuo, Si-Xue Cheng

Publisher page

Abstract

To overcome cancer-associated immunosuppression, we prepared a dual-targeting vector to deliver CpG oligodeoxynucleotides (ODN) to macrophages. The dual-targeting system composed of mannosylated carboxymethyl chitosan (MCMC)/hyaluronan (HA) for macrophage targeting and protamine sulfate for ODN complexation was prepared by self-assembly. The effects of ODN delivery on immune cells was studied in J774A.1 cells. Due to the enhanced delivery efficiency, the dual-targeting delivery system exhibits a higher immune stimulatory activity compared with the monotargeting delivery system containing either MCMC or HA, resulting in a dramatically enhanced secretion of proinflammatory cytokines and a successful shift to activated macrophages (M1). Besides macrophages, the influence of the delivery system on tumor cells (MCF-7) was also investigated. In MCF-7 cells, the increased expressions of nuclear transcription factor-κB (NF-κB), PIK3R3, and phosphorylated protein kinase B (p-Akt) caused by activated NF-κB and phosphoinositide 3-kinase/Akt signalings were observed. Nevertheless, upregulated Fas as well as Fas ligand (FasL) may induce Fas/FasL-mediated apoptosis, which results in the increased expressions of caspases in tumor cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Biomedical Polymers of Ministry of Education, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, People’s Republic of China

Funding

National Natural Science Foundation of China

References (67)

Show source-provided references
1. 10.1038/nature1067310.1038/nature10673 ↗
2. 10.1038/nature1203410.1038/nature12034 ↗
3. 10.1016/j.it.2015.02.00410.1016/j.it.2015.02.004 ↗
4. 10.1038/srep1427310.1038/srep14273 ↗
5. 10.1016/j.addr.2015.11.00910.1016/j.addr.2015.11.009 ↗
6. 10.1016/j.jconrel.2017.03.39510.1016/j.jconrel.2017.03.395 ↗
7. 10.1038/srep1663210.1038/srep16632 ↗
8. 10.1002/jcb.2589510.1002/jcb.25895 ↗
9. 10.1146/annurev.immunol.20.100301.06484210.1146/annurev.immunol.20.100301.064842 ↗
10. 10.1016/j.addr.2008.12.00810.1016/j.addr.2008.12.008 ↗
11. 10.1038/nri132910.1038/nri1329 ↗
12. 10.1002/anie.20150138010.1002/anie.201501380 ↗
13. 10.1038/sj.onc.121091110.1038/sj.onc.1210911 ↗
14. 10.1093/infdis/jit03610.1093/infdis/jit036 ↗
15. 10.1038/nature0720510.1038/nature07205 ↗
16. 10.1016/j.tvjl.2015.04.01510.1016/j.tvjl.2015.04.015 ↗
17. 10.1126/science.274.5288.78410.1126/science.274.5288.784 ↗
18. 10.1038/nrd292610.1038/nrd2926 ↗
19. 10.1530/ERC-12-039410.1530/ERC-12-0394 ↗
20. 10.1002/wnan.142110.1002/wnan.1421 ↗
21. 10.1016/j.msec.2016.03.04510.1016/j.msec.2016.03.045 ↗
22. 10.1186/s13104-017-2380-810.1186/s13104-017-2380-8 ↗
23. 10.1016/j.ijpharm.2015.09.06210.1016/j.ijpharm.2015.09.062 ↗
24. 10.1021/bc100436y10.1021/bc100436y ↗
25. 10.1002/adma.20150631210.1002/adma.201506312 ↗
26. 10.1016/j.nano.2015.08.00410.1016/j.nano.2015.08.004 ↗
27. 10.1016/j.jconrel.2015.11.00810.1016/j.jconrel.2015.11.008 ↗
28. 10.1039/C7CC01128H10.1039/C7CC01128H ↗
29. 10.1021/acs.bioconjchem.6b0067510.1021/acs.bioconjchem.6b00675 ↗
30. 10.1016/j.xphs.2017.03.02810.1016/j.xphs.2017.03.028 ↗
31. 10.1016/j.biomaterials.2016.09.03110.1016/j.biomaterials.2016.09.031 ↗
32. 10.1021/bc300611b10.1021/bc300611b ↗
33. 10.1073/pnas.131315211010.1073/pnas.1313152110 ↗
34. 10.1016/j.jconrel.2014.11.03310.1016/j.jconrel.2014.11.033 ↗
35. 10.1021/nn305466z10.1021/nn305466z ↗
36. 10.1016/j.biomaterials.2013.10.00310.1016/j.biomaterials.2013.10.003 ↗
37. 10.1371/journal.pone.016915410.1371/journal.pone.0169154 ↗
38. 10.1038/srep0053410.1038/srep00534 ↗
39. 10.1039/C5NR02240A10.1039/C5NR02240A ↗
40. 10.1002/adfm.20130234710.1002/adfm.201302347 ↗
41. 10.1039/C6CC09280B10.1039/C6CC09280B ↗
42. 10.1016/j.jconrel.2013.08.02110.1016/j.jconrel.2013.08.021 ↗
43. 10.1016/j.mtchem.2017.01.00610.1016/j.mtchem.2017.01.006 ↗
44. 10.1002/mabi.20160019510.1002/mabi.201600195 ↗
45. 10.1016/j.ijpharm.2016.10.06510.1016/j.ijpharm.2016.10.065 ↗
46. 10.2147/IJN.S8877410.2147/IJN.S88774 ↗
47. 10.1016/j.msec.2016.12.07210.1016/j.msec.2016.12.072 ↗
48. 10.1016/j.ijpharm.2016.10.00710.1016/j.ijpharm.2016.10.007 ↗
49. 10.1016/j.biomaterials.2007.12.02510.1016/j.biomaterials.2007.12.025 ↗
50. 10.1016/j.ijpharm.2016.04.03610.1016/j.ijpharm.2016.04.036 ↗
51. 10.1002/adhm.20160101210.1002/adhm.201601012 ↗
52. 10.1016/j.jconrel.2016.11.01210.1016/j.jconrel.2016.11.012 ↗
53. 10.1021/acs.chemmater.6b0373810.1021/acs.chemmater.6b03738 ↗
54. 10.1021/jacs.6b1138210.1021/jacs.6b11382 ↗
55. 10.1002/anie.20150981010.1002/anie.201509810 ↗
56. 10.1002/smll.20160233910.1002/smll.201602339 ↗
57. 10.2217/nnm-2016-011710.2217/nnm-2016-0117 ↗
58. 10.1172/JCI3153710.1172/JCI31537 ↗
59. 10.1016/j.biomaterials.2014.10.01710.1016/j.biomaterials.2014.10.017 ↗
60. 10.1038/ni102810.1038/ni1028 ↗
61. 10.1016/S1471-4906(03)00139-X10.1016/S1471-4906(03)00139-X ↗
62. 10.1038/sj.onc.120995410.1038/sj.onc.1209954 ↗
63. 10.4049/jimmunol.168.9.471110.4049/jimmunol.168.9.4711 ↗
64. 10.1172/JCI1199110.1172/JCI11991 ↗
65. 10.1038/cmi.2013.1410.1038/cmi.2013.14 ↗
66. 10.3389/fimmu.2017.0040310.3389/fimmu.2017.00403 ↗
67. 10.3748/wjg.v11.i22.344610.3748/wjg.v11.i22.3446 ↗